Patents by Inventor MATTEO BINDA

MATTEO BINDA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS, METHODS AND/OR KITS COMPRISING A RECOMBINANT HUMAN CD38-EXTRACELLULAR DOMAIN
    Publication number: 20240228651
    Abstract: A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies.
    Type: Application
    Filed: May 19, 2023
    Publication date: July 11, 2024
    Inventors: Vincenzo FAVALORO, Matteo BINDA, John A. Hall, Elizabeth Booth, Jody BERRY, Peter SCHWIND
  • COMPOSITIONS, METHODS AND/OR KITS COMPRISING A RECOMBINANT HUMAN CD38-EXTRACELLULAR DOMAIN
    Publication number: 20240132616
    Abstract: A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies.
    Type: Application
    Filed: May 18, 2023
    Publication date: April 25, 2024
    Inventors: Vincenzo FAVALORO, Matteo BINDA, John A. Hall, Elizabeth Booth, Jody BERRY, Peter SCHWIND
  • COMPOSITIONS, METHODS AND/OR KITS COMPRISING A RECOMBINANT HUMAN CD38-EXTRACELLULAR DOMAIN
    Publication number: 20240092929
    Abstract: A composition that binds to an anti-CD47 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD47 and/or a fragment thereof that interferes with binding activity of the anti-CD47 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD47 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD47 antibodies.
    Type: Application
    Filed: November 20, 2023
    Publication date: March 21, 2024
    Inventors: Vincenzo FAVALORO, Matteo BINDA, John A. Hall, Elizabeth Booth, Jody BERRY, Peter SCHWIND
  • Compositions, methods and/or kits comprising a recombinant human CD38- extracellular domain
    Patent number: 11708418
    Abstract: A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: July 25, 2023
    Assignee: GRIFOLS DIAGNOSTIC SOLUTIONS INC.
    Inventors: Vincenzo Favaloro, Matteo Binda, John A. Hall, Elizabeth Booth, Jody Berry, Peter Schwind
  • COMPOSITIONS, METHODS AND/OR KITS COMPRISING A RECOMBINANT HUMAN CD38-EXTRACELLULAR DOMAIN
    Publication number: 20210198376
    Abstract: A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies.
    Type: Application
    Filed: June 1, 2018
    Publication date: July 1, 2021
    Inventors: VINCENZO FAVALORO, MATTEO BINDA, JOHN A. HALL, ELIZABETH BOOTH, JODY BERRY, PETER A. SCHWIND